Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Dermatolog Treat ; 30(1): 45-48, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29676591

ABSTRACT

BACKGROUND: In Japan, more than five years have passed since emergence of the first three biologics, infliximab, adalimumab, and ustekinumab, became available in daily practice; however, no data for drug survival was reported from Japan. OBJECTIVE: To study the long-term drug survival of infliximab, adalimumab, and ustekinumab used for Japanese psoriatic patients. METHODS: We retrieved data on all patients treated with biological agents and calculated the long-term drug survival for infliximab, adalimumab, and ustekinumab using our psoriasis registry (Kurume Psoriasis Registry: KURUPR) consisted of 343 patients by the end of March 2017. We analyzed 103 treatment courses of 83 patients with all types of psoriasis, as well as 79 treatment courses of 62 patients with psoriasis vulgaris using the Kaplan-Meier method. RESULTS: Drug survival was higher for ustekinumab than infliximab and adalimumab in both settings, although there were no statistical differences. CONCLUSIONS: Previous studies of long-term drug survival in patients with psoriasis vulgaris showed significantly higher drug survival for ustekinumab than infliximab, and adalimumab. Our data showed similar tendency. Besides randomized clinical trials, drug survival data is useful because it reflects real-world management.


Subject(s)
Adalimumab/therapeutic use , Biological Products/therapeutic use , Infliximab/therapeutic use , Psoriasis/drug therapy , Ustekinumab/therapeutic use , Adult , Female , Humans , Japan , Male , Middle Aged , Registries , Retrospective Studies
2.
J Cutan Pathol ; 45(8): 623-628, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29752738

ABSTRACT

Adenodermatofibroma is a newly recognized variant of dermatofibroma characterized by dense proliferation of fibroblasts and histiocytes admixed with dilated glandular structures showing apocrine secretion. Only five cases of adenodermatofibroma have been reported to date. We report an additional case of adenodermatofibroma on the back of a 67-year-old female. In addition to the dilated glandular structures, nondilated eccrine units were present at the upper periphery of the lesion, above which the normal eccrine glands reside. Although decapitation secretion was observed in the nondilated eccrine units at the upper periphery of the lesion, this was not observed in the dilated glandular structures. The inner cells of the dilated glandular structures were S-100 positive, similar to those of the secretory portion of eccrine glands. We considered the glandular structures in our patient were derived from the entrapped eccrine units. We suggest that the term "apocrine metaplasia" be applied to eccrine units showing decapitation secretion.


Subject(s)
Eccrine Glands/pathology , Histiocytoma, Benign Fibrous/pathology , Skin Neoplasms/pathology , Sweat Gland Neoplasms/pathology , Aged , Female , Humans
5.
Dermatol Ther ; 27(3): 135-9, 2014.
Article in English | MEDLINE | ID: mdl-24102897

ABSTRACT

In this study, we report on the efficacy of combination therapy of second-generation antihistamine antagonist, fexofenadine hydrochloride, and leukotriene receptor inhibitor, montelukast sodium, for the treatment of 15 prurigo nodularis or pemphigoid nodularis patients, in whom conventional therapy was ineffective. All patients received 10 mg montelukast once a day and 240 mg fexofenadine twice a day for 4 weeks in addition to other medications they had been taking. We assessed the manifestations of the lesions and itching intensity before and after the therapy, and we evaluated each patient as (i) markedly improved, (ii) improved, (iii) slightly improved, (iv) no change, (v) worse. Two patients (13.3%) were evaluated as markedly improved, and the lesions of one patient completely disappeared. Three patients (20.0%) were evaluated as improved, and six patients (40.0%) as slightly improved. Thus, 11 of 15 cases (73.3%) improved by combination therapy of fexofenadine and montelukast, in which nine cases (75.0%) of prurigo nodularis and two cases (66.7%) of pemphigoid nodularis were involved. No patients revealed any side effects. This study revealed that combination therapy of fexofenadine and montelukast was effective for some patients with conventional therapy-resistant prurigo nodularis and pemphigoid nodularis.


Subject(s)
Acetates/therapeutic use , Histamine H1 Antagonists, Non-Sedating/therapeutic use , Leukotriene Antagonists/therapeutic use , Pemphigoid, Bullous/drug therapy , Prurigo/drug therapy , Quinolines/therapeutic use , Skin/drug effects , Terfenadine/analogs & derivatives , Acetates/administration & dosage , Adult , Aged , Aged, 80 and over , Cyclopropanes , Drug Administration Schedule , Drug Therapy, Combination , Female , Histamine H1 Antagonists, Non-Sedating/administration & dosage , Humans , Leukotriene Antagonists/administration & dosage , Male , Middle Aged , Pemphigoid, Bullous/diagnosis , Prurigo/diagnosis , Quinolines/administration & dosage , Skin/pathology , Sulfides , Terfenadine/administration & dosage , Terfenadine/therapeutic use , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...